Thalidomide in refractory vulvar ulcerations associated with Crohn's disease

Dermatology

Volumn 206, Issue 4, 2003, Pages 381-383

  Kolivras, Athanassios ^a,b   De Maubeuge, Josiane ^a   André, Josette ^a   Song, Micheline ^a  

^a Brugmann Universitary Hospital   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Crohn's disease; Neutrophil; Thalidomide; Ulceration; Vulva

Indexed keywords

MESSENGER RNA; METHYLPREDNISOLONE; ORNIDAZOLE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APHTHOUS ULCER; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; CONFERENCE PAPER; CROHN DISEASE; DERMATITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GIANT CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RECURRENT DISEASE; RNA DEGRADATION; SIDE EFFECT; TREATMENT OUTCOME; VULVA DISEASE;

ADULT; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THALIDOMIDE; TREATMENT OUTCOME; ULCER; VULVAR DISEASES;

EID: 0038654436     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069963     Document Type: Conference Paper

References (18)

1. Fenniche S, Mokni M, Haouet S, Ben Osman A: Crohn's disease of the vulva: 3 cases. Ann Dermatol Vénéréol 1997;124:629-632.
2. Thiriar S, Deroux E, Dourov N, Evrard L, Peny MO, Simon P, Parent D: Granulomatous vulvitis, granulomatous cheilitis: A single diagnosis? Dermatology 1998;196:455-458.
3. Franck N, Pelisse M, Moyal M, Escande JP: Vulvar Crohn's disease. Ann Dermatol Vénéréol 2002;129:1S576.
4. Laffitte E, Revuz J: Thalidomide; in Dubertret L (ed): Thérapeutique dermatologique. Paris, Flammarion, 2001, pp 1215-1219.
5. Sampaio EP, Hernandez MO, Carvalho DS, Sarno EN: Management of erythema nodosum leprosum by thalidomide: Thalidomide analogues inhibit M. leprae-induced TNF alpha production in vitro. Biomed Pharmacother 2002;56:13-19.
6. Ginsburg PM, Dassopoulos T, Ehrenpreis ED: Thalidomide treatment for refractory Crohn's disease: A review of the history, pharmacological mechanisms and clinical literature. Ann Med 2001;33:516-525.
7. Calabrese L, Fleischer AB: Thalidomide: Current and potential clinical applications. Am J Med 2000;108:487-495.
8. Johnston RE, Abdalla SH: Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002;43:351-354.
9. Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother 2002;56:4-12.
10. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17:135-139.
11. Bautitz J, Wabel S, Lochs H: Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200.
12. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modiliagni R: An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16:1117-1124.
13. Federman GL, Federman DG: Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000;75:842-844.
14. Hecker MS, Lebwohl MG: Recalcitrant pyoderma gangrenosum treated with thalidomide. J Am Acad Dermatol 1998;38:490-491.
15. Shek LP, Lim DL: Thalidomide in Behçet's disease. Biomed Pharmacother 2002;56:31-35.
16. Frances C: Dermatomucosal manifestations of Behçet's disease. Ann Méd Interne (Paris) 1999;150:535-541.
17. Micromedex Inc: Thalidomide (systemic): Precautions while using this medicine. Medline plus health information 2000, http://www.nlm.nih.gov/medlineplus/druginfo/thalidomidesystemic202692.html.
18. Bousvaros A, Mueller B: Thalidomide in gastrointestinal disorders. Drugs 2001;61:777-787.